Pharmaceuticals News and Research

RSS

European approval process for Eckert & Ziegler’s gallium-68 generator is successfully completed

Eckert & Ziegler Radiopharma GmbH has received a recommendation from the European Medicines Agency for approval of its pharmaceutical 68Ge/68Ga generators.

28 Jun 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

EMA CHMP adopts positive opinion for Bristol-Myers Squibb’s Daklinza for HCV treatment

Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.

27 Jun 2014

China Biologic prices follow-on offering of common stock at $38.00 per share

China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, today announced the pricing of a follow-on offering of 1,550,000 shares of common stock at a public offering price of $38.00 per share.

27 Jun 2014

Public health issues: Climate change; funding for Alzheimer's research

A medical expert calls for hospitals and health care officials to begin to plan for global warming problems, and The Wall Street Journal looks at new ways to finance research.

27 Jun 2014

Researchers develop new, cost-effective method for producing Janus capsules

Everything depends on how you look at them. Looking from one side you will see one face; and when looking from the opposite side - you will see a different one.

27 Jun 2014

Blocking enzyme Cdk5 could reduce brain damage after stroke

A drug that blocks the action of the enzyme Cdk5 could substantially reduce brain damage if administered shortly after a stroke, UT Southwestern Medical Center research suggests.

27 Jun 2014

Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, and QLT Inc., a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive agreement under which Auxilium plans to merge with QLT.

26 Jun 2014

Researchers discover way to use water as solvent to synthesize chemical products

Green-chemistry researchers at McGill University have discovered a way to use water as a solvent in one of the reactions most widely used to synthesize chemical products and pharmaceuticals.

26 Jun 2014

Researchers aim to fight cancer by developing 'personalised' cancer therapies

Cancer is incredibly complex, and each tumour is unique. This calls for a targeted approach. Researchers at KU Leuven's Department of Oncology, in Belgium, want to fight cancer by developing 'personalised' cancer therapies. To bolster their efforts, they have established the new Fund for Innovative Cancer Research.

26 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine!

25 Jun 2014

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its Phase 2b trial for once-daily, quadruple-action RoclatanTM, a combination of Aerie's triple-action RhopressaTM with latanoprost, a prostaglandin analogue (PGA).

25 Jun 2014

How will hepatitis C drug affect health care spending?

Elsewhere, pharmaceutical companies are upset over new rules for a drug discount program -- known as 340B.

25 Jun 2014

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.

25 Jun 2014

Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.

24 Jun 2014

Ferring Pharmaceuticals, Roche partner to make personalised infertility treatment possible

Ferring Pharmaceuticals and Roche have announced a collaboration to combine diagnostic testing technology from Roche with Ferring's human cell line derived recombinant follicle-stimulating hormone (human rFSH), a gonadotrophin currently in phase III development.

24 Jun 2014

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors.

24 Jun 2014

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana Therapeutics, Inc., and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs).

24 Jun 2014

Scientists turn to old class of antibiotics to fight superbugs resistant to modern medicine

Scientists at the University at Buffalo are turning to an old class of antibiotics to fight new superbugs resistant to modern medicine.

24 Jun 2014

Pharmaceuticals News and Research

European approval process for Eckert & Ziegler’s gallium-68 generator is successfully completed

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

EMA CHMP adopts positive opinion for Bristol-Myers Squibb’s Daklinza for HCV treatment

China Biologic prices follow-on offering of common stock at $38.00 per share

Public health issues: Climate change; funding for Alzheimer's research

Researchers develop new, cost-effective method for producing Janus capsules

Blocking enzyme Cdk5 could reduce brain damage after stroke

Auxilium Pharmaceuticals plans to merge with QLT

Researchers discover way to use water as solvent to synthesize chemical products

Researchers aim to fight cancer by developing 'personalised' cancer therapies

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

How will hepatitis C drug affect health care spending?

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Trevena's Phase 1b data for TRV130 published in the journal Pain

Ferring Pharmaceuticals, Roche partner to make personalised infertility treatment possible

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Scientists turn to old class of antibiotics to fight superbugs resistant to modern medicine

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence